<DOC>
	<DOCNO>NCT00434577</DOCNO>
	<brief_summary>Based result previous clinical PhaseI/II study , GSK1437173A lead GSK candidate Herpes Zoster ( HZ ) vaccine prevent episodes HZ ( shingle ) . This phase II study subdivide primary study ( 108494 ) three extension study ( 108516 , 108518 &amp; 108520 ) , consist one additional visit month 12 , 24 36 , respectively , first visit Zoster-003 primary study onwards . The aim primary 108494 study evaluate immunogenicity &amp; safety different dosage GSK1437173A vaccine healthy elderly population . The study population stratify age . The primary objective trial select best dosage GSK1437173A . The aim extension study evaluate persistence immune response induce candidate HZ vaccine long term period . No new subject enrol extension phase study .</brief_summary>
	<brief_title>Safety Immunogenicity Zoster Vaccine GSK1437173A Elderly Subjects</brief_title>
	<detailed_description>The Protocol Posting update order comply FDA Amendment Act , Sep 2007 .</detailed_description>
	<mesh_term>Herpes Zoster</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Subjects investigator believe comply requirement protocol . A male female age 60 year old time first vaccination . Written inform consent obtain subject Use investigational nonregistered product ( drug vaccine ) study vaccine ( ) within 30 day precede first injection study vaccine , plan use study period . Chronic administration ( defined 14 day ) immunosuppressant immunemodifying drug study period , except inhaled topical steroid allow . Administration plan administration vaccine foreseen study protocol within 2 week first study vaccine injection , exception influenza vaccine , administer 1 week precede 1 month first study vaccine injection . Previous vaccination HZ . History herpes zoster ( Shingles ) . Any confirm suspect immunosuppressive immunodeficient condition , base medical history physical examination ( laboratory testing require ) . History allergic disease reaction likely exacerbate component vaccine . Acute disease time enrolment . Acute chronic , clinically significant pulmonary , cardiovascular , hepatic renal functional abnormality , determine subject 's medical history physical examination assess investigator . Administration immunoglobulins and/or blood product within 3 month precede first injection study vaccine plan administration study period . History current drug and/or alcohol abuse .</criteria>
	<gender>All</gender>
	<minimum_age>60 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2012</verification_date>
	<keyword>GSK Biologicals</keyword>
	<keyword>Herpes Zoster ( HZ )</keyword>
	<keyword>Vaccine</keyword>
	<keyword>Varicella Zoster Virus ( VZV )</keyword>
	<keyword>Shingles</keyword>
</DOC>